Add to Twitter
Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG® (brigatinib)
– Phase 1/2 Data Being Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrated TAK-788 Extended the Time Until Disease Progression or Death by More Than Seven Months –

– Takeda’s Growing Lung Portfolio is Driven by a Dedication to Developing Innovative Therapies for People Living with NSCLC –